Butein ameliorates renal concentrating ability in cisplatin-induced acute renal failure in rats.
The present study examined whether the cisplatin-induced nephropathy could be ameliorated by administration of butein isolated from the stems of Rhus verniciflua STOCKS. The present study showed that polyuric profile was revealed in cisplatin-induced acute renal failure (ARF) rats associated with decreases in urinary sodium, potassium, chloride, and creatinine excretion, and osmolality. Among these renal functional parameters, urinary volume and osmolality were partially restored by administration of butein (10 mg/kg, i.p.), but electrolytes and creatinine excretion were not restored. Both solute-free water reabsorption and creatinine clearance were also significantly decreased in rats subjected to cisplatin. When butein was administered in rats with cisplatin-induced ARF for 4 d, solute-free water reabsorption was improved by 91% compared with that of cisplatin-induced ARF rats, but creatinine clearance was not restored. The expression levels of aquaporin 2 (AQP 2) in the inner, outer medulla, and cortex were significantly decreased in the kidney of ARF, which were partially reverted by administration of butein. In histological examination of the kidney, butein treatment partially prevented the lesions at tubules of renal cortex in cisplatin-induced ARF rats, while the lesions at glomeruli were not ameliorated. Taken together, butein ameliorates renal concentrating ability via up-regulation of renal AQP 2 water channel in rats with cisplatin-induced ARF without ameliorating effect on renal filtration defect.
Kang
Dae Gill
DG
Department of Herbal Resources, Professional Graduate School of Oriental Medicine, Wonkwang University, Iksan, Jeonbuk, Republic of Korea.
Lee
An Sook
AS
Mun
Yeun Ja
YJ
Woo
Won Hong
WH
Kim
Youn Chul
YC
Sohn
Eun Jin
EJ
Moon
Mi Kyong
MK
Lee
Ho Sub
HS
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D051399:Aquaporin 2; D020346:Aquaporins / Q000096:biosynthesis; D015153:Blotting, Western; D002599:Chalcone / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D047188:Chalcones; D002712:Chlorides / Q000652:urine; D002945:Cisplatin / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D007677:Kidney Function Tests; D007679:Kidney Medulla / Q000378:metabolism; D008297:Male; D011188:Potassium / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D012964:Sodium / Q000652:urine
D000970:Antineoplastic Agents; C496025:Aqp2 protein, rat; D051399:Aquaporin 2; D020346:Aquaporins; D047188:Chalcones; D002712:Chlorides; C040918:butein; D002599:Chalcone; D012964:Sodium; D003404:Creatinine; D002945:Cisplatin; D011188:Potassium